Navigation Links
Patent for Seminal RNAi innovation Cleared in Australia

Opposition in Australia to the grant of patent application to the Carnegie Institution of Washington in relation to the discovery of RNAi has been withdrawn.// This was announced by the Carnegie Institution of Washington and the University of Massachusetts Medical School. The opposition was originally filed by Benitec, an Australian biotechnogy company, in November 2004. Announcement of the withdrawal will be published in Australia's Official Journal of Patents on August 3, 2006.

Gary Kowalczyk, Carnegie's director of administration and finance, remarked: "The work by Drs. Mello, Fire, and others is widely recognized as the seminal intellectual property in the field of RNAi, and we are pleased that the process of granting a patent in Australia will now move forward. We look forward to companies in Australia licensing this intellectual property, and anticipate similar developments in other countries in the future."

The patent, known popularly as the Fire and Mello patent, was first granted in the United States by the United States Patent and Trademark Office in 2003. Additional patent rights in the United States and elsewhere are pending. To date, the Carnegie Institution, acting upon behalf of itself and the University of Massachusetts Medical School under an interinstitutional agreement, has granted approximately 50 non-exclusive licenses to companies using this invention.

The patent covers a process by which ribonucleic acid (RNA), the cellular material responsible for the transmission of genetic information, can silence a targeted gene within a living cell. The process, called RNA interference (RNAi), can shut down disease-causing genes or direct researchers to pathways for effective drug development.

Source Eurekalert
'"/>




Page: 1

Related medicine news :

1. Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations
2. HIV Patients Opposes Patenting Of AIDS Drug
3. Provigil Patent Extension Accorded To Cephalon
4. AIDS Sufferers Protest against Proposed Patent for Tenofovir
5. POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
6. Venus Remedies Files 5th International Patent Application
7. US Court Rules Against Lupin in Ramipril Patent Case
8. Canada: On Popular Demand, Tamiflu finds a Berth in the Directory of Patent Drugs
9. Compellis Pharmaceuticals Gets Patent for Obesity-Fighting Nasal Spray CP404
10. A Patented Device for Rapid Diagnosis of Diseases
11. Drop Patent Petition, Activists Ask Novartis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/21/2017)... ... ... broad access to life-saving drugs and rewarding the innovators who develop those drugs often ... , That was the message from Dana Goldman, PhD, Leonard D. Schaeffer Chair and ... who served as the keynote speaker for Western University of Health Sciences’ Ray Symposium ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... Christopher Salas-Wright finds that youth violence is declining—and at noteworthy rates. Between 2002 ... proportion of young people involved in violence in the United States. The study, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke Therapy Programs , ... kicked off its 4th annual Forum for Innovative Treatment Solutions (FITS), which runs ... Therapy for Mental Health and Addiction.” , FITS’ 2017 keynote presenters will ...
(Date:4/21/2017)... ... April 21, 2017 , ... Young Asset Protection, ... to communities throughout the greater Pittsburgh metropolitan region, is joining forces with the ... bicycles for differently-abled children. , Variety the Children’s Charity is a national organization ...
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t tell” applies ... project in the company’s esteemed VISION House demonstration project series. Manifesting the concept of ... of resources they need to live affordably and abundantly without unduly taxing the resources ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key ... to their offering. ... global pharmacogenomics market was valued at US$ 7,167.6 Mn in ... 2024, expanding at a CAGR of 5.6% from 2016 to ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
Breaking Medicine Technology: